272 related articles for article (PubMed ID: 15318940)
1. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.
Madrid MA; Lo RW
Breast Cancer Res; 2004; 6(5):R593-600. PubMed ID: 15318940
[TBL] [Abstract][Full Text] [Related]
2. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
3. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma.
Kim GY; Oh YL
Cytopathology; 2004 Dec; 15(6):315-20. PubMed ID: 15606364
[TBL] [Abstract][Full Text] [Related]
4. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
Tanner M; Gancberg D; Di Leo A; Larsimont D; Rouas G; Piccart MJ; Isola J
Am J Pathol; 2000 Nov; 157(5):1467-72. PubMed ID: 11073807
[TBL] [Abstract][Full Text] [Related]
5. HER 2 status in invasive breast cancer: immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.
Shirsat HS; Epari S; Shet T; Bagal R; Hawaldar R; Desai SB
Indian J Pathol Microbiol; 2012; 55(2):175-9. PubMed ID: 22771638
[TBL] [Abstract][Full Text] [Related]
6. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
Pathol Int; 2005 Jun; 55(6):318-23. PubMed ID: 15943788
[TBL] [Abstract][Full Text] [Related]
7. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M
Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
Ridolfi RL; Jamehdor MR; Arber JM
Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
[TBL] [Abstract][Full Text] [Related]
9. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.
Vocaturo A; Novelli F; Benevolo M; Piperno G; Marandino F; Cianciulli AM; Merola R; Donnorso RP; Sperduti I; Buglioni S; Mottolese M
Oncologist; 2006 Sep; 11(8):878-86. PubMed ID: 16951391
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
11. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
12. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
[TBL] [Abstract][Full Text] [Related]
13. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
Isola J; Tanner M; Forsyth A; Cooke TG; Watters AD; Bartlett JM
Clin Cancer Res; 2004 Jul; 10(14):4793-8. PubMed ID: 15269154
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
Bhargava R; Lal P; Chen B
Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
[TBL] [Abstract][Full Text] [Related]
15. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
[TBL] [Abstract][Full Text] [Related]
17. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
Sartelet H; Lagonotte E; Lorenzato M; Duval I; Lechki C; Rigaud C; Cucherousset J; Durlach A; Graesslin O; Abboud P; Doco-Fenzy M; Quereux C; Costa B; Polette M; Munck JN; Birembaut P
J Clin Pathol; 2005 Aug; 58(8):864-71. PubMed ID: 16049291
[TBL] [Abstract][Full Text] [Related]
18. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
[TBL] [Abstract][Full Text] [Related]
19. Determination of her-2/neu by chromogenic in situ hybridization on borderline (2+) immunohistochemistry cases in carcinoma breast.
Asif M; Khadim MT; Mushtaq S; Mamoon N; Akhtar F; Ali Z
Asian Pac J Cancer Prev; 2011; 12(1):211-4. PubMed ID: 21517259
[TBL] [Abstract][Full Text] [Related]
20. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization.
Ntoulia M; Kaklamanis L; Valavanis C; Kafousi M; Stathopoulos E; Arapantoni P; Mavroudis D; Georgoulias V; Lianidou ES
Clin Biochem; 2006 Sep; 39(9):942-6. PubMed ID: 16916505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]